Assessing the inhibition efficacy of clinical drugs against the main proteases of SARS‐CoV‐2 variants and other coronaviruses

Keywords

drug resistance / enzymatic activity / main protease / SARS‐CoV‐2

References

[1] Li P , Wang Y , Lavrijsen M , Lamers MM , de Vries AC , Rottier RJ , et al. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022; 32 (3): 322- 4.

[2] Owen DR , Allerton CMN , Anderson AS , Aschenbrenner L , Avery M , Berritt S , et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021; 374 (6575): 1586- 93.

[3] Hu Y , Lewandowski EM , Tan H , Zhang X , Morgan RT , Zhang X , et al. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. ACS Central Sci. 2023; 9 (8): 1658- 69.

[4] Hirotsu Y , Kobayashi H , Kakizaki Y , Saito A , Tsutsui T , Kawaguchi M , et al. Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2. Med. 2023; 4 (11): 813- 24.e4.

[5] Zuckerman NS , Bucris E , Keidar-Friedman D , Amsalem M , Brosh-Nissimov T . Nirmatrelvir resistance—de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure—a case report. Clin Infect Dis. 2024; 78 (2): 352- 5.

[6] Iketani S , Mohri H , Culbertson B , Hong SJ , Duan Y , Luck MI , et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature. 2023; 613 (7944): 558- 64.

[7] Unoh Y , Uehara S , Nakahara K , Nobori H , Yamatsu Y , Yamamoto S , et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem. 2022; 65 (9): 6499- 512.

[8] Chen X , Huang X , Ma Q , Kuzmič P , Zhou B , Zhang S , et al. Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nat Microbiol. 2024; 9 (4): 1075- 88.

[9] Ma C , Tan H , Choza J , Wang Y , Wang J . Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays. Acta Pharm Sin B. 2021.

[10] Sacco MD , Hu Y , Gongora MV , Meilleur F , Kemp MT , Zhang X , et al. The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition. Cell Res. 2022; 32 (5): 498- 500.

[11] Noske GD , de Souza Silva E , de Godoy MO , Dolci I , Fernandes RS , Guido RVC , et al. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease. J Biol Chem. 2023; 299 (3): 103004.

RIGHTS & PERMISSIONS

2024 2024 The Author(s). Quantitative Biology published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.